What are the key financial performance indicators from this report?

The key financial highlights include a substantial increase in net sales (7.7% quarterly, 7.9% year-to-date), an improved gross margin rate (26.3% quarterly), and significant growth in net earnings (17.4% quarterly). Operating cash flow also saw a notable increase, reaching $559.2 million year-to-date. Diluted earnings per share were $0.56 for the quarter.

What major strategic move did CVS make during this period?

CVS announced the acquisition of Eckerd Operations for $2.15 billion. This acquisition is intended to expand its retail drugstore presence, particularly in high-growth markets like Florida and Texas, and significantly bolster its Pharmacy Benefit Management (PBM) segment with the addition of Eckerd Health Services.

How did the company's operational expenses change?

Total operating expenses increased by 11.0% for the quarter and 9.1% year-to-date. As a percentage of net sales, operating expenses rose slightly to 20.7% for the quarter and 20.4% year-to-date. This increase was primarily attributed to higher payroll and benefit expenses, advertising costs, and initial costs related to the Eckerd acquisition.

What is the company's outlook on liquidity and capital resources?

CVS expects to fund its operations and growth through cash flow from operations, supplemented by commercial paper and long-term borrowings. The company anticipates sufficient liquidity to cover working capital, capital expenditures, and debt service for the next twelve months and the foreseeable future, including plans for longer-term financing for the Eckerd acquisition.

CVS 10-Q Quarterly Report Q3 FY2004 — Revenue, Net Income, EPS

Summary

CVS Corporation's Q2 2004 10-Q filing reveals a period of robust sales growth and improved profitability, driven primarily by its Retail Pharmacy segment. Net sales increased by 7.7% for the quarter and 7.9% year-to-date, with pharmacy sales showing strong performance at 8.0% and 8.7% growth respectively. This growth outpaced the front store sales, leading to pharmacy sales comprising nearly 70% of total revenue. The company also saw an expansion in its gross margin rate to 26.3% for the quarter, up from 25.4% in the prior year, attributed to increased generic drug sales and improved inventory management. Financially, net earnings for the quarter rose by 17.4% to $234.5 million, translating to diluted EPS of $0.56. The company's operating cash flow significantly improved, reaching $559.2 million for the first six months of the year, indicating strong operational performance. A major development during the quarter was the announcement of the acquisition of Eckerd Operations for $2.15 billion, which is expected to expand CVS's market presence and bolster its PBM segment. While the integration of Eckerd presents opportunities, management acknowledges the need for significant operational improvements to enhance Eckerd's performance, and has not guaranteed the success of these initiatives.

Key Highlights

1Net sales increased by 7.7% to $6.94 billion for the thirteen weeks ended July 3, 2004, and by 7.9% to $13.76 billion for the twenty-six weeks ended July 3, 2004, compared to the prior year periods.
2Gross margin rate improved to 26.3% for the quarter and 26.2% year-to-date, up from 25.4% in the prior year, driven by higher generic drug sales and improved inventory management.
3Net earnings available to common shareholders increased by 17.4% to $230.8 million ($0.56 per diluted share) for the thirteen weeks ended July 3, 2004.
4Net cash provided by operating activities significantly increased to $559.2 million for the twenty-six weeks ended July 3, 2004, compared to $345.0 million in the prior year.
5The company announced a significant acquisition of Eckerd Operations for $2.15 billion, aiming to expand its retail footprint and strengthen its PBM segment.
6Investment in property and equipment increased to $464.4 million for the first six months of 2004, supporting store openings, relocations, and the company's real estate development program.
7Pro forma net earnings, reflecting SFAS No. 123 for stock-based compensation, were $225.0 million for the quarter, with pro forma diluted EPS of $0.54.

CVS HEALTH Corp Quarterly Report for Q3 Ended Jul 3, 2004

Summary

Key Highlights

Frequently Asked Questions